Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
pegilodecakin (LY3500518)
i
Other names:
LY3500518, PEG-rHuIL-10, AM0010, AM 0010, AM-0010
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Eli Lilly
Drug class:
IL-10 agonist
‹
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
pembrolizumab + LY3500518
Resistant: C3 – Early Trials
pembrolizumab + LY3500518
Resistant
:
C3
pembrolizumab + LY3500518
Resistant: C3 – Early Trials
pembrolizumab + LY3500518
Resistant
:
C3
TMB-H
Non Small Cell Lung Cancer
TMB-H
Non Small Cell Lung Cancer
nivolumab + LY3500518
Sensitive: C4 – Case Studies
nivolumab + LY3500518
Sensitive
:
C4
nivolumab + LY3500518
Sensitive: C4 – Case Studies
nivolumab + LY3500518
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.